Core Transaction Overview - Core Scientific is involved in a transaction with CoreWeave, where shareholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each share of Core Scientific, valuing the deal at approximately $9.0 billion [2]. Investigation Details - The Ademi Firm is investigating Core Scientific for potential breaches of fiduciary duty and other legal violations related to the transaction with CoreWeave [1]. - The investigation focuses on whether the Core Scientific board of directors is fulfilling their fiduciary duties to all shareholders, particularly in light of the transaction's terms [3]. Transaction Restrictions - The transaction agreement imposes significant penalties on Core Scientific if it accepts competing bids, which may unreasonably limit other potential transactions [3].

Investment Rating - The report indicates a positive outlook for cash returns in the Chinese market, with expectations for aggregate dividends and buybacks to reach Rmb3.0tn and Rmb0.6tn respectively in 2025, reflecting a year-on-year growth of 10% and 35% [1][11]. Core Insights - Chinese listed companies are experiencing record-high cash returns, driven by strong policy support and conservative cash return practices, with a significant increase in dividends and buybacks anticipated in the coming years [1][11]. - The report highlights a preference among investors for "Old China" companies that prioritize shareholder returns, with a correlation between cash spending on dividends/buybacks and increased company valuations [2][45]. - There is a growing appetite for cash return strategies among various types of Chinese investors, as these strategies are perceived as offering superior returns compared to bonds in a low-interest rate environment [3][53]. Summary by Sections Cash Returns Growth - Following the "Nine Measures" policy released in April 2024, over 4300 companies recorded Rmb2.7tn in dividends in 2024, with a dividend payout ratio of 39%, up from 37% in 2023 [11][12]. - The expectation for total dividends in 2025 is Rmb3.0tn, supported by high-single digit earnings growth and an increase in payout ratios [11][12]. Buybacks and Financial Incentives - A-share and offshore companies repurchased approximately Rmb160bn and Rmb300bn worth of shares in 2024, marking increases of 56% and 79% year-on-year [20][31]. - The re-lending program for corporate buybacks has seen strong adoption, with over 620 A-share firms announcing credit agreements totaling Rmb133bn [31][25]. Investment Strategies - The GS China Shareholder Returns Portfolio has been refreshed to include 30 GS-Buy rated companies, which are actively returning capital to shareholders [63][64]. - The GS Chinese Prominent 10 portfolio focuses on large-cap companies investing heavily in growth while also providing decent cash returns, appealing to investors seeking a mix of growth and income [64][65]. Sector Analysis - Companies in traditional sectors like Financials and Utilities tend to favor dividends, while those in New Economy sectors like TMT and Healthcare are more inclined towards buybacks [37][46]. - The report categorizes over 6700 Chinese listed companies into "New China" and "Old China," noting differing investor preferences for capital allocation between these groups [46][45].

Synovus' Transformation and Growth - Synovus has undergone a multi-year transformation, enhancing its ability to succeed [6] - The company is capitalizing on growth tailwinds with stronger loan growth, balanced core deposit growth, and continued healthy non-interest revenue growth [11, 21] - Synovus is focused on long-term shareholder value creation [14] Financial Performance and Guidance - The Common Equity Tier 1 Ratio decreased by 440 bps from 3Q22 [13] - Allowance For Credit Losses increased by 112 bps from 3Q22 [13] - Wholesale Funding/Assets increased by 11 bps from 3Q22 [13] - The company projects 3%-6% loan growth and 3%-6% core deposit growth for 2025 [35] - Synovus anticipates 3%-7% adjusted revenue growth and 3%-7% adjusted non-interest expense growth in 2025 [35] Strategic Initiatives - Synovus is targeting a 20-30% expansion of relationship managers over the next 3 years [26] - Strategic growth segments include Middle Market, Specialty Lending, and CIB [22]

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. due to allegations of deceptive promotion and sale of illegitimate versions of Wegovy®, leading to a significant drop in the company's stock price [2][3]. Group 1: Allegations and Impact - Hims & Hers Health, Inc. announced a collaboration with Novo Nordisk on April 29, 2025, to sell Wegovy® on its platform [2]. - Novo Nordisk terminated its partnership with Hims on June 23, 2025, citing deceptive practices that jeopardized patient safety, resulting in a 34.6% decline in Hims' share price, closing at $41.98 [2]. - The lawsuit claims that Hims failed to disclose its engagement in selling illegitimate versions of Wegovy® and the risk of partnership termination with Novo Nordisk [3]. Group 2: Legal Proceedings - Shareholders interested in leading the class action must file a motion by August 25, 2025, and can remain absent class members if they choose not to participate [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for allegedly misleading investors about its business prospects during the pandemic [1][2]. Group 1: Allegations - The lawsuit claims that Petco's pandemic-related growth was unsustainable and that its business model focused on premium pet food was overstated [2]. - It is alleged that the company downplayed the severity of issues affecting its business and the necessary changes to address these issues [2]. - The complaint states that Petco overstated its ability to achieve sustainable and profitable growth, leading to a decline in stock price when the truth was revealed [2]. Group 2: Class Action Participation - Investors who purchased Petco securities between January 14, 2021, and June 5, 2025, may be eligible to participate in the class action [1][3]. - Shareholders interested in serving as lead plaintiffs can contact the firm, but participation is not required to be eligible for recovery [3]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is successful [4].

🔥 JUST IN: Metaplanet now has 128,073 shareholders, more than doubling in just 3 months. https://t.co/0G06olyPpl ...

Company Strategy & Competitive Advantages - The company aims for a long-term Return on Equity (ROE) target of 15%[8] - The company operates where specialized knowledge provides a competitive edge[8, 11] - A decentralized structure enables quick responses to changing market conditions[11] - The company focuses on long-term risk-adjusted returns and shareholder value creation[7, 8] Financial Performance & Capital Management - In 2024, Insurance net premiums written were $10.5 billion, and Reinsurance & Monoline Excess net premiums written were $1.4 billion[20] - As of December 31, 2024, total debt was $2.841 billion, and common equity was $8.395 billion, resulting in a debt-to-capital ratio of 25.3%[42] - The company has returned $7.5 billion to shareholders through dividends and share repurchases since 2006, representing 55% of net income[49] - The company actively manages capital, including the issuance of subordinated debt in 2023 ($185 million at 5.700%), 2024 ($300 million at 5.100%), and planned issuances in 2025 ($250 million at 4.250%) and 2026 ($300 million at 4.125%)[46] Investment Portfolio - As of December 31, 2024, fixed maturity securities constituted 75.1% of the investment portfolio, totaling $22.397 billion[38] - Cash and cash equivalents represented 6.4% of the portfolio, amounting to $1.891 billion[38] - "Alternative" investments accounted for 18.5% of the portfolio, totaling $5.491 billion[38]

South Korea’s ambitious plan to improve corporate governance standards got a boost after the parliament voted to approve changes that will help protect the rights of minority shareholders https://t.co/OBq2Hb27ea ...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Napco Security Technologies, Inc. (NASDAQ: NSSC) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Napco Security caused the company to misrepresent Napco’s overall expected growth and strength in the Company’s hardware division, including, among other things, confidence in Napco’s ability to achieve i ...

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of NET Power Inc. related to misleading statements about Project Permian [1][2] Group 1: Allegations of Misrepresentation - Insiders at NET Power allegedly caused the company to misrepresent the likelihood of completing Project Permian on schedule, indicating it would be significantly more expensive due to supply chain issues and site-specific challenges [2] - Projections regarding the time and capital needed to complete Project Permian were deemed unrealistic, suggesting a significant negative impact on the company's business and financial results [2] - Public statements made by NET Power were materially false and misleading at all relevant times, according to the federal securities lawsuit [2] Group 2: Shareholder Actions - Shareholders who purchased NPWR shares prior to June 9, 2023, are encouraged to contact Kuehn Law for potential legal action, as there may be limited time to enforce their rights [3] - Kuehn Law offers to cover all case costs and does not charge investor clients, emphasizing the importance of shareholder participation in maintaining market integrity [4]